 |
|
|
| |
HBeAg Levels Predict HBeAg Seroconversion During the Immune Clearance Phase of Chronic Hepatitis B in Patients Receiving Nucleot(s)ide Analogue Therapy
|
| |
| |
Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
Julianne Bayliss,1 Alexander Thompson,1,2 Gillian Rosenberg,1 Anuj Gaggar,3 Kathryn Kitrinos,3 Mani Subramanian,3 Patrick Marcellin,4 Edward Gane,5 Henry L.Y. Chan,6 Xin Li,1 Danni Colledge,1 Margaret Littlejohn,1 Lilly Yuen,1 Rosalind Edwards,1 Kathleen Jackson,1 Sara Bonanzinga,1 Rachel Hammond,1 Scott Bowden,1 Stephen Locarnini,1 Peter Revill1
1Victorian Infectious Diseases Reference Laboratory (VIDRL), Melbourne, Victoria, Australia; 2St Vincent's Hospital, Melbourne, Victoria, Australia; 3Gilead Sciences, Inc., Foster City, CA; 4Hôpital Beaujon, University of Paris, Clichy, France; 5New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand; 6The Chinese University of Hong Kong, Hong Kong SAR
|
| |
|
|
|
|
|
